IQVIA Research & Development Solutions on LinkedIn: IQVIA (2024)

"Throughout the last decade, #clinicaltrials have contributed to the rapid advancement of global #oncology, paved the way for cures to many diseases and extend survival time in #patient populations with poor prognoses.But this does not come without setbacks; modern approaches to oncology #research have changed significantly in the last 10 years and bring a variety of new challenges to research teams." Today's #askmeanything details common obstacles to oncology studies that #clinicalresearch professionals are working hard to overcome. KCR's Medical Operations team shares insight about the areas of #oncologyresearch that require development, improvement or new solutions. Check it out!👇https://lnkd.in/dcW8xcNf#KCRCRO #AMA #KCRAMA #medicine #cancerresearch #oncologytrials #KCRSolutions #KCRConsulting

20

𝐓𝐡𝐞 𝐧𝐞𝐰 "𝐀𝐧𝐭𝐢 𝐂𝐑𝐎" 𝐥𝐨𝐨𝐤𝐢𝐧𝐠 𝐭𝐨 𝐝𝐢𝐬𝐫𝐮𝐩𝐭 𝐭𝐡𝐞 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 Lindus Health, known as the "anti-CRO," has launched a comprehensive CRO tailored for sponsors aiming to bring diagnostic products to market. With a track record of enrolling over 30,000 patients in diagnostic trials across the US, UK, and Europe, Lindus Health offers expertise in various therapeutic areas like oncology, infectious disease, respiratory, and women's health. Their new offering, the "All-in-One Diagnostics CRO," aims to streamline diagnostics clinical trials by leveraging their experience, network, and proprietary technologies. Lindus Health addresses the unique challenges of diagnostics studies, such as large-scale recruitment requirements, by offering specialized recruitment tactics and expert regulatory guidance. #cro #disruption

5

1 Comment

"Patient groups have become a powerhouse in R&D"Those of us in #raredisease have known this, but good to see my former employer IQVIA speaking to this and providing the data to back it through their amazing think tank #InstituteforHumanDataScience. According to Murray Aitken, Executive Director of the Institute... "Patient groups... invested $1.6 billion into therapeutics in the past 15 years and many are sponsoring clinical trials, creating registries, and driving trial enrollment.""It’s not just the heavy hitters — such as the The Michael J. Fox Foundation for Parkinson's Research, the Cystic Fibrosis Foundation, and the Multiple Myeloma Research Foundation - MMRF —among the 3,300-plus patient groups in the U.S. that are steering industry R&D. Smaller organizations are also making a difference by striking deals with life sciences companies."This is a great article to read for any level group to understand that you can make an huge impact as a patient group. There is a lot to think about and prioritize, but know you are not alone and there are a lot of really cool models and successful groups to learn from.If you are struggling with starting or maintaining a registry, need tools to help your population, data collection in general, or anything else related to technology come talk to us. Our single focus is to empower rare disease communities with tools and technologies to help patients and families as well as to prepare the way with data to attract potential investors of treatments and therapies in their space.#acrosshealthcare #acrossmatrix #JoinTheMatrixWebsite: https://lnkd.in/gKJeq7hk https://lnkd.in/gszcbMqx

31

#ClinicalDevelopment has a chronic issue with trial enrolment, with almost a fifth of cancer trial sites enrolling only a single patient. 🧍To help sponsors predict and maximize enrolment, we launched our Health Check and Trial Rescue service. 👩⚕️The new service will allow sponsors to take a proactive and data-driven approach from the trial planning stage onwards, minimizing the risk of single patient sites. 📉Discover how we plan to overcome the problem in Technology Networks, here. 👇https://lnkd.in/eEVCAgQW#ClinicalTrials #Innovation

4

I highly encourage you to take a few minutes and read this blog. Jennifer give her insight on clinical trials from the view of a clinician and as a patient. Excellent blog!

8

Exciting news from the 2024 #SCOPESummit! John Campbell, Head of Decentralized Trials at Walgreens, revealed how they're revolutionizing #clinicaltrials. Leveraging their vast retail pharmacy network, Walgreens aims to make trials more accessible and diverse. By utilizing data and innovative recruitment strategies, they're rapidly assembling patient cohorts for various studies.Walgreens is expanding its impact in diagnostics, cancer detection, vaccines, and more. This pioneering approach promises to reshape the future of clinical research. Learn more in this article on The Clinical Trial Vanguard.

5

Such a great article with so many truths from my colleague Marcy Kravet!"Sponsors should look beyond the same group of large sites that stand out in a data set and start looking for the sites that would stand out to a patient." I appreciate Marcy's comments because she has walked the walk and talked the talk from Pharma perspective with regards to Feasibility. Its easy to believe the process is broken and yields the same 5% of Sites over and over, but hearing your peers who have managed the process share these details only confirms it further. Especially in Oncology with seemingly more and more competition each and every day!A few comments that stuck out to me were:1. Over half (52%) of Oncology participants live over an hour away from a trial Site.2. Data driven Feasibility has its flaws and does not show motivation, community connections and patient relationships.3. Traditional, data driven, Feasibility reduces Sites to data points. Its only natural that data driven approaches bring us back to the same "top-tier" Sites continuously. This is where the data is! Additionally, every Sponsor is using the same "data" and going to the same Sites as you are, further perpetuating the cycle of data driven Feasibility. All of this data creates an insane level of competition and congestion at the same Sites.4. In 2024 lets challenge what a "good" Site means.#feasibility #clinicaltrials #sites Inato

11

3 Comments

CROs who would like to leverage data insights to find the best investigators for their clinical trials should mark their calendars for April 9. Our Data Science experts Barbara Argibay Gonzalez and Elke Ydens will host a joint webinar with EUCROF, the European CRO Federation. Find more info and register via the link below. 👇#ClinicalResearch #ClincialTrials #CRO #InvestigatorSelection #DataScience #TAScan

13

📢 In the challenging world of Oncology, VPs of Clinical Development face numerous struggles. Let's dive into these pain points while exploring how Real-World Evidence (RWE) can positively impact their work.1️⃣ Complex Patient Populations:VPs often encounter heterogeneous patient populations, making it difficult to draw meaningful conclusions from traditional clinical trials. RWE steps in here by leveraging real-world data, obtained from diverse sources like electronic health records, claims databases, and patient registries. This enables VPs to gain a deeper understanding of patient characteristics, treatment patterns, and outcomes in the real world, enhancing clinical development decision-making.2️⃣ Long and Costly Trials:Clinical trials in Oncology are infamous for being time-consuming and expensive. Traditional trial designs often involve prolonged patient recruitment periods, significant costs, and immense patient burden. RWE can offer a solution by complementing and supplementing clinical trial data. By utilizing RWE, VPs can potentially reduce trial lengths by incorporating real-world insights, accelerating the development and delivery of innovative therapies.3️⃣ Limited Availability of Clinical Data:Access to high-quality clinical data can be a crucial bottleneck for VPs. Gathering sufficient clinical data within restrictive timelines poses a significant challenge. RWE can bridge this gap by tapping into readily available, real-world data sources. By leveraging RWE, VPs can access a broader range of patient data, including long-term follow-up and real-world outcomes, leading to better evidence generation for regulatory submissions and clinical decision-making.4️⃣ Evolving Regulatory Landscape:Navigating the ever-changing regulatory environment in Oncology can be a substantial barrier. VPs must adapt to evolving guidelines and requirements from regulatory agencies. RWE has gained recognition as a valuable tool in assessing treatment effectiveness and safety. By incorporating robust RWE methodologies, VPs can more effectively fulfill regulatory obligations and gain insights that may support label expansions or post-approval commitments.5️⃣ Patient-Centric Approach:Patient-centeredness is a key focus for VPs, as improving patient outcomes is the ultimate goal. RWE, driven by real-world patient experiences, helps align clinical development strategies with patient needs. By capturing real-world treatment patterns, adherence rates, and patient-reported outcomes, VPs can optimize trial design, enhance patient engagement, and ultimately deliver meaningful therapies to those in need.#ClinicalDevelopment #Oncology #RealWorldEvidence

1

It’s always exciting to engage with professionals working along the clinical trials spectrum to talk about patient engagement, and to learn what they are doing to bring new therapies to patients. My first engagement at the Clinical Trial Supply Forum last week in Brussels made me appreciate the mammoth task of getting therapies to patients in clinical trials, on time and at the right quality. We agreed that early input into the protocol and trial design by the right stakeholders (including patient advocates and experts!) could solve many challenges currently seen in clinical trials. See my key takeways below!www.patient-co-next.com#patientengagement #patientcentricity #patientadvocacy #clinicaltrials #research #drugdevelopment #patientinsights #patientrecruitment #clinicaloperations #pfmd #patientjourney #clinicaltrialsupply #decentralisedclinicaltrials #directtopatient #dct #dtp #clinicaltrialsupplyforum #pharmaIQ #caroljarvis #clinicaltrialsday

6